drugset / Trial / NCT05327647
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
Phase 2
Recruiting
160 enrolled
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR) · collabCancer Research Society · collab
Non-randomizedSequentialSingle-blindTreatment
Summary
This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.
Timeline
- Start
- 2022-06-23
- Primary completion
- 2026-09-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bicalutamide | Other / unclassified | 150 mg | Oral |